Streetbeat News

Earnings

SLRX

Salarius Pharmaceuticals reported worse-than-expected Q2 earnings per share (EPS) results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:22 pm

TISI

Shares of Team Inc. (TISI) are trading lower following the company's announcement of a year-over-year decrease in Q2 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:21 pm

AMRS

CANO

JYNT

RGTI

TSAT

YTEN

US stocks traded mixed with the Dow Jones gaining around 100 points while the NASDAQ and S&P 500 fell. Energy shares jumped by 1.6% while information technology shares fell by 0.8%. Amyris, Inc. (AMRS) shares shot up 141% after filing for Chapter 11 bankruptcy. Telesat Corporation (TSAT) shares rose 39% after reporting Q2 results and a $2.1 billion deal with MDA. Rigetti Computing, Inc. (RGTI) shares were up 49% following a narrower-than-expected quarterly loss. Yield10 Bioscience, Inc. (YTEN) shares dropped 58% after announcing a $3.7 million public offering. Cano Health, Inc. (CANO) shares were down 70% after reporting worse-than-expected Q2 results and pursuing a sale process. The Joint Corp. (JYNT) shares fell 19% after Q2 operating highlights.

Portfolio Pulse from Lisa Levin

August 11, 2023 | 4:19 pm

VIEW

View Inc. reported better-than-expected Q2 financial results, leading to a rise in its share price. The company also announced that it has regained compliance with the Nasdaq minimum bid price requirements.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:15 pm

NVVE

Nuvve Holding reported its Q2 financial results, which led to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:12 pm

BTMD

Biote Corp reported worse-than-expected Q2 EPS results and issued FY23 revenue guidance, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:11 pm

MNDY

monday.com Ltd. (NASDAQ:MNDY) is expected to report Q2 earnings of 17 cents per share, compared to a loss of 33 cents per share a year ago. Revenue is projected to be $169.27 million, up from $123.72 million in the same period last year. The company's shares closed at $155.32 on Thursday, up 1.9%. Several analysts have revised their price targets for the company, with the highest being $240 from Goldman Sachs.

Portfolio Pulse from Lisa Levin

August 11, 2023 | 4:07 pm

VTGN

VistaGen Therapeutics reported a year-over-year decrease in Q1 revenue results, leading to a drop in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:04 pm

BFRI

Biofrontera reported worse-than-expected Q2 financial results, causing its shares to trade lower. The company also reiterated its FY23 revenue growth guidance.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:02 pm

MEDS

Trxade Health (NASDAQ:MEDS) is set to release its latest quarterly earnings report on August 14, 2023. Analysts estimate an earnings per share (EPS) of $-0.75. The company's past performance shows a trend of beating EPS estimates but experiencing a drop in share price. The stock is currently trading at $9.0, down 59.52% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 4:02 pm